JP2023533938A5 - - Google Patents

Info

Publication number
JP2023533938A5
JP2023533938A5 JP2023500011A JP2023500011A JP2023533938A5 JP 2023533938 A5 JP2023533938 A5 JP 2023533938A5 JP 2023500011 A JP2023500011 A JP 2023500011A JP 2023500011 A JP2023500011 A JP 2023500011A JP 2023533938 A5 JP2023533938 A5 JP 2023533938A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
cancer
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023500011A
Other languages
English (en)
Japanese (ja)
Other versions
JP7759374B2 (ja
JP2023533938A (ja
Filing date
Publication date
Priority claimed from PCT/CN2020/100134 external-priority patent/WO2021000935A1/en
Application filed filed Critical
Publication of JP2023533938A publication Critical patent/JP2023533938A/ja
Publication of JP2023533938A5 publication Critical patent/JP2023533938A5/ja
Application granted granted Critical
Publication of JP7759374B2 publication Critical patent/JP7759374B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023500011A 2019-07-04 2021-07-02 Hpk1阻害剤およびその使用 Active JP7759374B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019094634 2019-07-04
PCT/CN2020/100134 WO2021000935A1 (en) 2019-07-04 2020-07-03 Hpk1 inhibitors and uses thereof
CNPCT/CN2020/100134 2020-07-03
PCT/CN2021/104206 WO2022002237A1 (en) 2019-07-04 2021-07-02 Hpk1 inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2023533938A JP2023533938A (ja) 2023-08-07
JP2023533938A5 true JP2023533938A5 (cg-RX-API-DMAC7.html) 2024-07-10
JP7759374B2 JP7759374B2 (ja) 2025-10-23

Family

ID=74100919

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022500151A Active JP7633989B2 (ja) 2019-07-04 2020-07-03 Hpk1阻害剤およびその使用
JP2023500011A Active JP7759374B2 (ja) 2019-07-04 2021-07-02 Hpk1阻害剤およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022500151A Active JP7633989B2 (ja) 2019-07-04 2020-07-03 Hpk1阻害剤およびその使用

Country Status (16)

Country Link
US (2) US12612424B2 (cg-RX-API-DMAC7.html)
EP (2) EP3994133A4 (cg-RX-API-DMAC7.html)
JP (2) JP7633989B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220044495A (cg-RX-API-DMAC7.html)
CN (2) CN114555585B (cg-RX-API-DMAC7.html)
AU (2) AU2020298649B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022000064A2 (cg-RX-API-DMAC7.html)
CA (1) CA3145973A1 (cg-RX-API-DMAC7.html)
DK (1) DK4175951T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981368T3 (cg-RX-API-DMAC7.html)
FI (1) FI4175951T3 (cg-RX-API-DMAC7.html)
IL (1) IL289612B2 (cg-RX-API-DMAC7.html)
MA (1) MA56462A (cg-RX-API-DMAC7.html)
MX (2) MX2022000271A (cg-RX-API-DMAC7.html)
TW (1) TWI878319B (cg-RX-API-DMAC7.html)
WO (2) WO2021000935A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2021000935A1 (en) 2019-07-04 2021-01-07 Qilu Regor Therapeutics Inc. Hpk1 inhibitors and uses thereof
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
CN116456985A (zh) * 2020-09-23 2023-07-18 深圳市原力生命科学有限公司 作为hpk1调节剂的嘧啶及吡啶衍生物和其使用方法
US20230399327A1 (en) * 2020-10-28 2023-12-14 Adlai Nortye Biopharma Co., Ltd. High activity hpk1 kinase inhibitor
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN117295737A (zh) * 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
CN117295748A (zh) * 2021-03-08 2023-12-26 缆图药品公司 Map4k1抑制剂
JP2024510176A (ja) * 2021-03-08 2024-03-06 ブループリント メディシンズ コーポレイション Map4k1阻害剤
TW202246263A (zh) * 2021-03-23 2022-12-01 大陸商杭州阿諾生物醫藥科技有限公司 Hpk1激酶抑制劑化合物
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN117377673A (zh) * 2021-03-29 2024-01-09 林伯士萨顿公司 Hpk1拮抗剂和其用途
TW202304906A (zh) * 2021-04-08 2023-02-01 大陸商杭州阿諾生物醫藥科技有限公司 高活性hpk1激酶抑制劑
MX2024000751A (es) * 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.
WO2023001794A1 (en) 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
EP4377318A4 (en) * 2021-07-30 2025-06-04 BeiGene, Ltd. PYRROLO[2,3-B PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND USE THEREOF
WO2023083299A1 (zh) * 2021-11-12 2023-05-19 微境生物医药科技(上海)有限公司 作为hpk1抑制剂的稠环化合物
WO2023134608A1 (zh) * 2022-01-11 2023-07-20 微境生物医药科技(上海)有限公司 作为hpk1抑制剂的稠环化合物
WO2023245329A1 (en) * 2022-06-20 2023-12-28 Biofront Ltd Multi-kinase inhibitors, compositions thereof, and methods of using the same
CN117447470B (zh) * 2023-02-20 2026-05-01 杭州医学院 一种作为hpk1抑制剂的吡咯并吡啶衍生物、制备方法及其应用
CN116813692A (zh) * 2023-06-29 2023-09-29 凌科药业(杭州)有限公司 含磷化合物、其药物组合物及其用途
WO2025096647A1 (en) * 2023-10-30 2025-05-08 Nimbus Saturn, Inc. Methods of treating tumors
WO2025137168A2 (en) 2023-12-19 2025-06-26 Regor Pharmaceuticals, Inc. Salt and solid forms of a hpk1 inhibitor
WO2025255343A1 (en) * 2024-06-06 2025-12-11 Dana-Farber Cancer Institute, Inc. Pyrrolopyrimidine inhibitors of wild-type and mutant lrrk2

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007041511A2 (en) 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
WO2007135398A1 (en) 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
WO2008003766A2 (en) 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
CA2673003A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
WO2008110508A1 (en) 2007-03-09 2008-09-18 Glaxo Group Limited Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity
WO2009084695A1 (ja) * 2007-12-28 2009-07-09 Carna Biosciences Inc. 2-アミノキナゾリン誘導体
US20100121052A1 (en) 2008-06-20 2010-05-13 Rama Jain Novel compounds for treating proliferative diseases
EP2248907A1 (en) 2009-05-08 2010-11-10 Rijksuniversiteit Groningen Gluco-oligosaccharides comprising (alpha 1-->4) and (alpha 1-->6) glycosidic bonds, use thereof, and methods for providing them
WO2012135631A1 (en) * 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
US9708336B2 (en) 2014-01-22 2017-07-18 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
US20170137426A1 (en) * 2014-03-28 2017-05-18 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
CN106188029B (zh) * 2015-05-05 2018-09-18 山东轩竹医药科技有限公司 二并环类间变性淋巴瘤激酶抑制剂
ES2921257T3 (es) 2016-06-20 2022-08-22 Daegu Gyeongbuk Medical Innovation Found Nuevo derivado de imidazopiridina, procedimiento para prepararlo y composición farmacéutica que contiene el mismo como ingrediente activo para prevenir o tratar el cáncer
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11180482B2 (en) 2016-11-30 2021-11-23 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
EP3587422A4 (en) 2017-02-22 2020-05-06 Daegu-Gyeongbuk Medical Innovation Foundation PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE
EP3596075B1 (en) 2017-03-15 2023-10-11 F. Hoffmann-La Roche AG Azaindoles as inhibitors of hpk1
US20200071326A1 (en) 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
WO2018215668A1 (en) 2017-05-26 2018-11-29 Glenmark Pharmaceuticals S.A. Novel inhibitors of map4k1
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN109721620B (zh) 2017-10-27 2022-05-13 药捷安康(南京)科技股份有限公司 Hpk1抑制剂及其用途
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020235902A1 (ko) 2019-05-17 2020-11-26 주식회사 보로노이 헤테로고리 융합 피리미딘 유도체 및 이의 용도
WO2021000935A1 (en) 2019-07-04 2021-01-07 Qilu Regor Therapeutics Inc. Hpk1 inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
PH12022551014A1 (en) Substituted tricyclic compounds
JP2014500870A5 (cg-RX-API-DMAC7.html)
JP2008535902A5 (cg-RX-API-DMAC7.html)
RS20230516A1 (sr) Postupci za lečenje raka prostate
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
JP2019014758A5 (cg-RX-API-DMAC7.html)
JP2023500483A5 (cg-RX-API-DMAC7.html)
JP2011509949A5 (cg-RX-API-DMAC7.html)
IL311873A (en) Combination therapy for treating malignancies
JP2021530453A5 (cg-RX-API-DMAC7.html)
JP2021530487A5 (cg-RX-API-DMAC7.html)
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
JP2015512943A5 (cg-RX-API-DMAC7.html)
JP2019506392A5 (cg-RX-API-DMAC7.html)
MX2022014192A (es) Metodos para tratar el cancer de prostata.
NZ726365A (en) Combinations for treating cancers
JP2018511643A5 (cg-RX-API-DMAC7.html)
RU2011124894A (ru) Триазолотиадиазоловый ингибитор протеинкиназы с-мет
JP2025504379A5 (cg-RX-API-DMAC7.html)
MX2023013715A (es) Regímenes de dosis de ecubectedina.
JP2019534865A5 (cg-RX-API-DMAC7.html)
JP2013544892A5 (cg-RX-API-DMAC7.html)
JP2019065009A5 (cg-RX-API-DMAC7.html)
MX2025009374A (es) Compuesto que contiene trifluorometilsulfonilo
MX2023009962A (es) Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso.